Intranasal Delivery of Thermostable Subunit Vaccine for Cross-Reactive Mucosal and Systemic Antibody Responses Against SARS-CoV-2

Despite the remarkable efficacy of currently approved COVID-19 vaccines, there are several opportunities for continued vaccine development against SARS-CoV-2 and future lethal respiratory viruses. In particular, restricted vaccine access and hesitancy have limited immunization rates. In addition, cu...

Descripción completa

Detalles Bibliográficos
Autores principales: Nguyen, Khue G., Mantooth, Siena M., Vrabel, Maura R., Zaharoff, David A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9110812/
https://www.ncbi.nlm.nih.gov/pubmed/35592324
http://dx.doi.org/10.3389/fimmu.2022.858904

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9110812/
https://www.ncbi.nlm.nih.gov/pubmed/35592324
http://dx.doi.org/10.3389/fimmu.2022.858904

Ejemplares similares